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Abstract
Cryptosporidium parvum is an important human pathogen and potential bioterrorism agent. This
protozoan parasite cannot salvage guanine or guanosine and therefore relies on inosine 5′-
monophosphate dehydrogenase (IMPDH) for biosynthesis of guanine nucleotides and hence for
survival. Since C. parvum IMPDH is highly divergent from the host counterpart, selective inhibitors
could potentially be used to treat cryptosporidiosis with minimal effects on its mammalian host. A
series of 1,2,3-triazole containing ether CpIMPDH inhibitors are described. A structure-activity
relationship study revealed that a small alkyl group on the alpha-position of the ether was required
with the (R)-enantiomer significantly more active than the (S)-enantiomer. Electron-withdrawing
groups in the 3- and/or 4-positions of the pendent phenyl ring were best and conversion of the
quinoline containing inhibitors to quinoline-N-oxides retained inhibitory activity both in the presence
and absence of bovine serum albumin. The 1,2,3-triazole CpIMPDH inhibitors provide new tools
for elucidating the role of IMPDH in C. parvum and may serve as potential therapeutics for treating
cryptosporidiosis.
Introduction
Inosine 5′-monophosphate dehydrogenase (IMPDH) catalyzes the nicotinamide-adenine
dinucleotide (NAD+)-dependent oxidation of inosine 5′-monophosphate (IMP, 1) to
xanthosine 5′-monophosphate (XMP, 3), the first committed and rate limiting step in the
biosynthesis of guanosine monophosphate (GMP, 4, Scheme 1).1 IMPDH controls the guanine
nucleotide pool, and therefore plays an integral role in cellular proliferation.2 Human IMPDH
exists in two isoforms, IMPDH1 and IMPDH2, which have high (85%) sequence identity.
Human IMPDH1 is most prevalent in leukocytes and lymphocytes, while IMPDH2 is found
in greatest abundance in rapidly proliferating cells, including neoplastic cells.3 IMPDH has
emerged as an attractive therapeutic target for the treatment of various conditions,4 including
cancer5 and viral infections.6 IMPDH inhibitors have also been used clinically as
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immunosuppressants, prompting further interest in utilizing this class of therapeutics for
treating other autoimmune diseases.7
IMPDH may also be a target for antimicrobial chemotherapy, though its utility can be
compromised if the microorganism can salvage guanine and/or xanthine. Prokaryotic and
eukaryotic IMPDHs have divergent amino acid sequences and display significantly different
kinetic properties, suggesting that it should be possible to develop selective inhibitors.1, 8
Prokaryotic IMPDHs are resistant to the known human IMPDH inhibitor mycophenolic acid,
demonstrating that selective inhibition is possible. IMPDH is a promising target for the
treatment of cryptosporidiosis, a major cause of diarrhea and malnutrition initiated by the
protozoan parasites Cryptosporidium parvum and a related pathogenic species
Cryptosporidium hominis.9 These organisms can cause severe gastroenteritis and diarrhea,
which can be life threatening in immunocompromised individuals. In addition, C. parvum is
a potential bioterrorism agent. Interestingly, both C. parvum and C. hominis rely exclusively
on the IMPDH-mediated pathway for guanine nucleotide synthesis by salvaging and converting
adenosine to 1 and then subsequently to 4.10–12 C. parvum IMPDH (CpIMPDH) appears to
have been obtained from an ε-proteobacterium by lateral gene transfer.13 These observations
suggest that selective inhibition of CpIMPDH may provide an attractive means for parasite-
specific inhibition, while minimizing potential side-effects on the human (or other mammalian)
host.
Our laboratories have been seeking to identify and optimize low molecular weight molecules
capable of selectively inhibiting CpIMPDH in order to provide lead compounds for therapeutic
development to treat cryptosporidiosis.14 During a high throughput screening (HTS) campaign
5 was identified as a moderately potent and very selective inhibitor of CpIMPDH (EC50 = 3.3
± 0.2 μM) with no detectable activity against the human enzyme (EC50 ≫ 50 μM).15 The
compound demonstrated uncompetitive inhibition with respect to 1 and noncompetitive
(mixed) inhibition with respect to NAD+. It was also shown to bind the nicotinamide subsite
and to directly or indirectly impose on the ADP site.15 Herein, we report a structure-activity
relationship (SAR) study for this class of inhibitors, including a key structural change to the
amide functional group.
Results and Discussion
Chemistry
Various analogs of 5 that contain the amide functional group were prepared according to
Scheme 1. Ethyl glyoxylate was allowed to react with c-PrMgBr to give a corresponding
alcohol that was subsequently converted to bromide 7 (R = c-Pr) with carbon tetrabromide and
triphenylphosphine. Various other bromide derivatives of 7 were commercially available.
Treatment of 7 with 1-naphthol in the presence of base (K2CO3) gave ester 8 (X = CH). The
ester was saponified with 3N sodium hydroxide in THF to give acid 9 (X = CH), which was
subsequently converted to amide 10 (X = CH) with the aid of EDCI·HCl in anhydrous
dichloromethane (DCM). In the case of a quinoline analog of 10 (X = N), the acetyl chloride
derivative 11 was first converted to amide 12, which was treated with 4-hydroxyquinoline to
give 10 (X = N).
Analogs of 5 that replaced the amide functional group with a 1,2,3-triazole were prepared
according to Scheme 2. The common intermediate in the synthesis of these derivatives was
propargyl ether 16. This intermediate was prepared using several different routes. In the first
route (R1 = Me or H), 13 was alkylated utilizing either a Mitsonobu reaction with a propargyl
alcohol or by treatment with propargyl bromide in the presence of potassium carbonate. The
route employing the Mitsonobu reaction also afforded enantiomerically enriched ethers stating
with (S)- or (R)-but-3-yn-2-ol. When R1 = i-Pr and R2 = CO2H, the acid 14 (prepared via
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Scheme 1) was reduced to the corresponding alcohol with LiAlH4 and then oxidized to
aldehyde 15 under Swern conditions.16 When R1 = Et, R2 = CO2Et, the ester 14 (prepared via
Scheme 1) was reduced directly to aldehyde 15 with DIBAL in THF at −78 °C. Aldehyde 15
was converted to the corresponding alkyne utilizing the two step procedure described by Corey
and Fuchs.17 Ether 16 was converted to 1,2,3-triazole 17 in the presence of an aryl azide and
CuI.18 In the case of N-oxide derivatives, 16 (X or Y = N) was first treated with m-CPBA. The
N-oxide of 16 was then converted to 17 (X or Y = N+-O−).
Biology
IC50 determinations for CpIMPDH inhibition—Evaluation of CpIMPDH inhibitory
activity for the various prepared compounds was conducted utilizing an assay for the
conversion of 1 to 3 by monitoring the production of NADH by fluorescence in the presence
of varying inhibitor concentrations.15 For all the compounds reported herein, the IC50 values
were determined in three independent experiments. The average IC50 values and standard
deviations are reported in Tables 1 and 2. It is commonly observed that antimicrobial or
antiparasitic activity of compounds can be adversely affected by nonspecific binding to serum
proteins, which sequesters the compounds preventing interaction with the target.19 This in
vitro effect can translate into poor efficacy in vivo due to low free fraction concentration of
compound that can enter the pathogenic organism.20 To characterize the non-specific binding
of inhibitors, IC50 values were also determined in the presence of 0.05% fatty acid free bovine
serum albumin (BSA). In addition, none of the compounds displayed inhibitory activity against
human IMPDH2 (< 10% at 5 μM).
Fusing an additional benzo-ring onto the phenyl ether of 5 resulted in a compound (18)
demonstrating a 3-fold increase in CpIMPDH inhibitory activity (Table 1). However, when
the methyl group on the alpha-carbon of the amide was replaced with a phenyl (19) inhibitory
activity was lost. An isopropyl group (20) was well tolerated, but surprisingly a cyclopropyl
(21) was not. The naphthyl ether could also be replaced with a 4-quinolinyl ether resulting in
a compound (22) exhibiting an IC50 of 0.66 μM. The amide derivatives that demonstrated
CpIMPDH inhibitory activity were then evaluated for enzyme inhibitory activity in the
presence BSA. The CpIMPDH inhibitory activities of 18, 20 and 22 were only slightly
decreased in the presence of BSA.
Early in the SAR study of 5, attempts were made to find a bioisostere for the amide functional
group.21 Given the many reported successes with the use of 1,2,3-triazole in ligand design20–
24 including as a replacement for amide bonds, this heterocycle was incorporated into an analog
of 18 resulting in 23.25–30 Gratifyingly, 23 demonstrated increased CpIMPDH inhibitory
activity with an IC50 of 130 nM (Table 2). However, the IC50 value increased significantly to
780 nM in the presence of BSA. Also, unlike the amide series replacing the methyl substituent
with an isopropyl (24) in the 1,2,3-triazole series was not tolerated. In addition, moving the
para-chloro group on the pendent phenyl to the ortho-position (25) was detrimental. However,
adding a chlorine atom on the naphthyl ether (26) or replacing the naphthyl with a 4-quinolinyl
(27) resulted in further increases in inhibitory activity, with IC50 values of 87 and 24 nM,
respectively. Unfortunately, the inhibitory activity for both compounds was eroded in the
presence of BSA. Given the potency of 27, various other changes were made to this compound.
For example, removing the methyl group (28) resulted in a significant loss of activity.
Introduction of an additional chloride atom in the 3-position of the pendent phenyl (29) retained
potent inhibitory activity. Introduction of 4-cyano (30) or 3-chloro-4-cyano (31) substituents
on the pendent phenyl resulted in IC50 values of 140 and 40 nM, respectively. Next, the
enantiomers of 29 were evaluated. The (R)-enantiomer (32), which demonstrated an IC50 of 9
nM, was significantly more potent (~ 14-fold) than the (S)-enantiomer (33). A similar finding
was observed with the enantiomers 34 and 35. The connectivity of the ether to the quinoline
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ring was changed to the 5-position (36) with retention of potent inhibitory activity.
Interestingly, the inhibitory activity of this quinoline derivative was not as adversely affected
as the other analogs by the presence of BSA. Finally, in an attempt to increase the polarity of
the 1,2,3-triazole series with the goal of mitigating the effects of BSA on inhibitory activity,
the N-oxide of 27 was evaluated. The IC50 value of 37 was 29 nM and in the presence of BSA
only slightly increased to 50 nM. This 2-fold increase was less than seen with many of the non-
N-oxide derivatives and was reminiscent of the results observed with the amide series. Several
other N-oxide derivatives in the 1,2,3-triazole series, such as 38–41 also demonstrated potent
inhibitory activity both in the presence and absence of BSA.
Conclusions
An SAR study of the alpha-phenoxide anilide derivative 5 that was previously shown to be a
moderately potent and very selective inhibitor of C. parvum IMPDH,15 an essential enzyme
to this important human pathogenic protozoan parasite and potential bioterrorism agent, was
undertaken. Initially, the amide was retained and addition of a fused ring onto the phenyl ether,
resulting in 1-naphthyl or 4-quinolinyl ethers, was shown to increase CpIMPDH inhibitory
activity. The active amide analogs retained inhibitory activity in the presence of BSA.
Replacement of the amide with the bioisostere 1,2,3-triazole resulted in increased CpIMPDH
inhibitory activity, but activity was eroded in the presence of BSA. Further increases in
CpIMPDH inhibitory activity were accomplished with various electron-withdrawing groups
in the 3- and/or 4-positions, but not the 2-position, of the pendent phenyl ring. Also, a small
alkyl group (i.e. methyl) was required on the alpha-position of the ether with the (R)-
enantiomers demonstrating significantly more activity than the (S)-enantiomers. Finally,
conversion of the quinolines to quinoline-N-oxides retained potent inhibitory activity both in
the presence and absence of BSA. The 1,2,3-triazole CpIMPDH inhibitors described herein
can serve as new tools for elucidating the role of IMPDH in C. parvum and related organisms.
These inhibitors could also serve as potential lead compounds for therapeutic development for
the treatment of cryptosporidiosis.
Experimental Section
Chemistry Material and Methods
Unless otherwise noted, all reagents and solvents were purchased from commercial sources
and used without further purification. All reactions were performed under nitrogen atmosphere
unless otherwise noted. The NMR spectra were obtained using a 400 or 500 MHz spectrometer.
All 1H NMR spectra are reported in δ units ppm and are referenced to tetramethylsilane (TMS)
if conducted in CDCl3 or to the central line of the quintet at 2.49 ppm for samples in d6-DMSO.
All chemical shift values are also reported with multiplicity, coupling constants and proton
count. All 13C NMR spectra are reported in δ units ppm and are referenced to the central line
of the triplet at 77.23 ppm if conducted in CDCl3 or to the central line of the septet at 39.5 ppm
for samples in d6-DMSO. Coupling constants (J values) are reported in hertz. Column
chromatography was carried out on SILICYCLE SiliaFlash silica gel F60 (40–63 μm, mesh
230–400). High-resolution mass spectra were obtained using a SX-102A mass spectrometer
(JEOL USA, Inc., Peabody, MA), a LCT mass spectrometer (Micromass Inc., Beverly, MA)
or a Q-tof Ultima API mass spectrometer. All melting points were taken in glass capillary tubes
on a Mel-Temp® apparatus and are uncorrected. All test compounds had a purity ≥ 95% as
determined by either elemental analysis or high performance liquid chromatography (HPLC)
analysis, unless otherwise noted. The elemental composition of compounds agreed to within
± 0.4% of the calculated values. Chemical and enantiomeric purities were determined using
high performance liquid chromatography (HPLC) analysis on a Hewlett-Packard 1100 Series
instrument equipped with a quaternary pump and a Daicel Chiralpak AD column (250 × 4.6
mm). UV absorption was monitored at λ = 254 nm. The injection volume was 1 μL. HPLC
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gradient was 50 % n-hexane and 50 % i-propanol with a flow rate of 1.0 mL/min. In some
cases, chemical purity was determined using a Agilent 1100 HPLC instrument equipped with
a quaternary pump and a Zorbax® SB-C8 column (30 × 4.6 mm, 3.5 μm). UV absorption was
monitored at λ = 254 nm. The injection volume was 5 μL. HPLC gradient went from 5 %
acetonitrile and 95 % water to 95 % acetonitrile and 5 % water (both solvents contain 0.1%
trifluoroacetic acid) over 1.9 min with a total run time of 2.5 min and a flow rate of 3.0 mL/
min.
Synthesis of ethyl α-bromocyclopropaneacetate (7, R = C-Pr)
A flame dried two-neck round bottom flask fitted with a reflux condenser and nitrogen inlet
was charged with anhydrous THF, freshly activated Mg (120 mg, 4.95 mmol) and a catalytic
amount of iodine. A small portion of cyclopropyl bromide dissolved in THF was added. After
initiation of reflux, the reaction mixture was cooled to −20 °C and the remaining cyclopropyl
bromide (500 mg, 4.13 mmol) was gradually added. After 30 min a freshly distilled solution
of glyoxalate 9 (549 mg, 5.37 mmol) in THF was added over a 10 min period and the resulting
solution was stirred at −20 °C for 2 h before being quenched with a small amount of water.
After 10 min the reaction mixture was further diluted with water (50 mL) and extracted with
ethyl acetate (3 × 50 mL). The organic extracts were combined, dried over anhydrous
MgSO4, filtered, concentrated in vacuo and purified by column chromatography eluting with
ethyl acetate/n-hexane (a gradient of 10–20 %) to furnish ethyl α-hydroxycyclopropaneacetate
(422 mg, 71 %) as a viscous oil. The oil (350 mg, 2.43 mmol) was dissolved in anhydrous
DCM and cooled to 0 °C. Then Ph3P (2.04 gm, 7.78 mmol) was added followed by CBr4 (1.20
gm, 3.64 mmol). The reaction mixture was stirred at 0 °C for 2 h and then concentrated in
vacuo. The Ph3PO was precipitated by addition of n-hexane and removed by filtration. The
crude reaction mixture was purified by flash column chromatography eluting with ethyl acetate/
n-hexane (1:9) to furnish ethyl α-bromocyclopropaneacetate (7, R = c-Pr): (311 mg, 62 %
yield).
General procedure for the synthesis of 2-(1-naphthalenyloxy)acetic acids (9). Exemplified for
2-cyclopropyl-2-(1-naphthalenyloxy)acetic acid (9, R = C-Pr)
To a solution of 1-naphthol (170 mg, 1.18 mmol) in anhydrous DMF (10 mL) was added
K2CO3 (510 mg, 3.53 mmol) and ethyl α-bromocyclopropaneacetate (295 mg, 1.41 mmol).
The mixture was stirred at room temperature for 2 h and then diluted with water (50 mL) and
then extracted with ethyl acetate (3 × 50 mL). The organic extracts were combined, washed
with brine, dried over anhydrous MgSO4, filtered, concentrated in vacuo and purified by flash
column chromatography using a mixture of ethyl acetate/n-hexane (1:9) to furnish ethyl 2-
cyclopropyl-2-(1-naphthalenyloxy)acetate (8, R = c-Pr, 296 mg, 93 %) as a white solid. The
ester (250 mg, 0.92 mmol) was dissolved in 20 mL THF:H2O (2:1) and then 3N NaOH (111
mg, 2.77 mmol) was added. The reaction was heated at 80 °C for 6 h. After cooling, the reaction
mixture was quenched with 1N HCl to a pH ~7 and then extracted with chloroform. The organic
extract was dried over anhydrous MgSO4, filtered, concentrated in vacuo and purified by flash
column chromatography eluting with a mixture of ethyl acetate/n-hexane (2:1) to furnish 2-
cyclopropyl-2-(1-naphthalenyloxy)acetic acid (9, R = c-Pr) (136 mg, 61 %) as a white solid.
General procedure for the synthesis of N-(4-chlorophenyl)-2-(1-naphthalenyloxy)acetamides
(10, X= CH). Exemplified for N-(4-chlorophenyl)-2-cyclopropyl-2-(1-naphthalenyloxy)
acetamide (21)
To a solution of 2-cyclopropyl-2-(1-naphthalenyloxy)acetic acid (120 mg, 0.49 mmol) and 4-
chloroaniline (44.0 μL, 0.49 mmol) in anhydrous DCM (10 mL) under N2 cooled at 0 °C was
added EDCI·HCl (187.9 mg, 0.98 mmol) portion wise. The resulting solution was stirred at
room temperature for 12 h. The reaction mixture was diluted with water (50 mL) and extracted
Maurya et al. Page 5
J Med Chem. Author manuscript; available in PMC 2010 August 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
with ethyl acetate (3 × 100 mL). The organic extracts were combined, washed with brine, dried
over anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was purified by flash
column chromatography using ethyl acetate/n-hexane (a gradient of 5–10 %) to furnish 21 (148
mg, 86 %) as a white solid. mp 204–206 °C; 1H NMR (CDCl3, 400 MHz) δ 0.65–0.78 (m,
4H), 1.52 (m, 1H), 4.41 (d, J = 6.4 Hz, 1H), 6.70 (d, J = 8.0 Hz, 1H), 7.25 (d, J = 6.0 Hz, 3H),
7.43 (d, J = 8.4 Hz, 2H), 7.61–7.70 (m, 3H), 7.97 (s, 1H), 8.22 (d, J = 8.4 Hz, 1H), 8.34 (d, J
= 8.0 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 2.70, 3.16, 14.42, 82.72, 108.01, 115.68, 121.47,
122.03, 122.96, 127.64, 128.43, 129.28, 129.63, 130.07, 132.96, 135.61, 152.83, 169.27; ESI-
HRMS for C21H17ClNO2 (M−H)+ calcd. 350.0948; found 350.0956.
N-(4-chlorophenyl)-2-(1-naphthalenyloxy)propanamide (18) : mp 146–148 °C; 1H NMR
(CDCl3, 400 MHz) δ 1.79 (d, J = 6.8 Hz, 3H), 4.98 (q, J = 6.8, 13.2 Hz, 1H), 6.87 (d, J = 7.6
Hz, 1H), 7.26 (d, J = 8.4 Hz, 2H), 7.37 (t, J = 8.4 Hz, 1H), 7.46 (d, J = 8.8 Hz, 2H), 7.56 (dd,
J = 7.8, 12.5 Hz, 3H), 7.86 (m, 1H), 8.24–8.32 (m, 2H). 13C NMR (CDCl3, 100 MHz): δ 19.08,
76.26, 107.41, 121.42, 121.54, 122.47, 125.91, 126.04, 126.16, 127.03, 128.14, 129.26, 129.95,
134.93, 135.75, 152.61, 170.58; Anal. (C19H16ClNO2) C, H, N.
N-(4-chlorophenyl)-α-(1-naphthalenyloxy)benzeneacetamide (19): yield 92 %; mp 176–
178 °C; 1H NMR (CDCl3, 400 MHz) δ 5.86 (s, 1H), 6.88 (d, J = 8.0 Hz, 1H), 7.26–7.61 (m,
11H), 7.68 (d, J = 7.2 Hz, 2H), 7.87 (d, J = 7.2 Hz, 1H), 7.37 (d, J = 8.0 Hz, 1H), 8.44 (s,
1H). 13C NMR (CDCl3, 100 MHz): δ 81.09, 107.87, 121.41, 121.47, 122.58, 125.66, 126.01,
126.27, 126.61, 127.02, 128.25, 129.12, 129.15, 129.27, 130.06, 134.94, 135.71, 135.98,
152.34, 168.11; Anal. (C24H18ClNO2) C, H, N.
N-(4-chlorophenyl)-3-methyl-2-(1-naphthalenyloxy)butanamide (20): yield 91 %; mp
150–152 °C, 1H NMR (CDCl3, 400 MHz) δ 1.22 (dd, J = 6.8, 22.8 Hz, 6H), 2.54 (m, 1H), 4.68
(d, J = 4.4 Hz, 1H), 6.83 (d, J = 8.0 Hz, 1H), 7.25 (m, 2H), 7.35 (t, J = 8.0 Hz, 1H), 7.40 (d,
J = 8.8 Hz, 2H), 7.52 (d, J = 8.0 Hz, 1H), 7.54–7.60 (m, 2H), 7.86 (m, 1H), 8.01 (s, 1H), 8.38
(m, 1H); 13C NMR (CDCl3, 100 MHz) δ 17.47, 19.54, 32.48, 84.51, 106.81, 121.53, 122.20,
125.71, 126.12, 127.04, 128.15, 129.21, 129.97, 134.92, 135.57, 153.52, 169.68; Anal.
(C21H20ClNO2) C, H, N.
Synthesis of 2-bromo-N-(4-chlorophenyl)propanamide (12)
To a solution of 4-chloroaniline (400 mg, 3.13 mmol) in anhydrous DCM at room temperature
under a nitrogen atmosphere was added slowly 2-bromopropanoyl chloride (474 μL, 4.7
mmol). The reaction mixture was stirred at room temperature for 2 h and then diluted with
water (50 mL) and extracted with ethyl acetate (3 × 50 mL). The organic extracts were
combined, washed with brine, dried over anhydrous MgSO4 and concentrated in vacuo to give
2-bromo-N-(4-chlorophenyl)propanamide, which was used without further purifications.
Synthesis N-(4-chlorophenyl)-2-[[4-quinolinyl]oxy]propanamide (22)
To a solution of 4-hydroxyquinoline (100 mg, 0.69 mmol) in anhydrous DMF under a nitrogen
atmosphere was added K2CO3 (286 mg, 2.10 mmol) and a solution of 2-bromo-N-(4-
chlorophenyl)propanamide (218 mg, 0.83 mmol) in DMF. The reaction mixture was stirred
for 12 h at room temperature before being diluted with water (50 mL) and extracted with
chloroform (3 × 50 mL). The combined organic extracts were dried over anhydrous MgSO4,
filtered, concentrated in vacuo and purified by flash chromatography using ethyl acetate/n-
hexane (1:9) to furnish 22 (207 mg, 92 % yield) as a white solid. mp 170–172 °C, 1H NMR
(CDCl3, 400 MHz) δ 1.83 (d, J = 6.4 Hz, 3H), 5.06 (q, J = 6.8, 13.6 Hz, 1H), 6.76 (d, J = 5.6
Hz, 1H), 7.28 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 7.61 (t, J = 8.0 Hz, 1H), 7.77 (t,
J =7.6 Hz, 1H), 8.09 (d, J = 7.2 Hz, 1H), 8.26 (d, J = 8.4 Hz, 1H), 8.76 (d, J = 5.6 Hz,
1H); 13C NMR (CDCl3, 100 MHz) δ 18.72, 75.83, 102.05, 122.27, 121.32, 121.58, 126.61,
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129.34, 129.60, 130.34, 130.51, 135.40, 149.74, 151.48, 159.47, 169.20; ESI-HRMS for
C18H16N2O2Cl (M+H)+ calcd. 327.0900; found 327.0901.
General procedure for the preparation propargyl ether 16 via the Mitsonobu reaction.
Exemplified for 1-[(1-methyl-2-propyn-1-yl)oxy]naphthalene (16, R1 = Me, X = Y = CH)
To a solution of 1-naphthol (200 mg, 1.38 mmol) and but-3-yn-2-ol (146 mg, 2.07 mmol) in
anhydrous DCM (10 mL) under a nitrogen atmosphere and at 0 °C was added Ph3P (435 mg,
1.66 mmol) portion wise. The reaction mixture was stirred for 10 min and then DEAD (360
mg, 2.07 mmol) (70 % solution in toluene) was slowly added. The resulting reaction solution
was stirred at the room temperature for 24 h and then diluted with water (50 mL) and extracted
with chloroform (3 × 50 mL). The combined organic extracts were washed with brine, dried
over anhydrous MgSO4, filtered, concentrated in vacuo and the residue was purified by flash
column chromatography using ethyl acetate/n-hexane (a gradient of 5–10 %) to furnish 1-[(1-
methyl-2-propyn-1-yl)oxy]naphthalene (176 mg, 65 %) as a viscous oil.
General procedure for the preparation propargyl ether 16 via the Corey-Fuchs reaction.
Exemplified for the synthesis of 1-(1-methylethyl)-2-propyn-1-yl]oxy]naphthalene (16, R1 =
I-Pr, X = Y = CH)
A the solution of 14 (R1 = i-Pr, R2 = CO2H, X = Y = CH, 880 mg, 3.27 mmol) in anhydrous
THF was cooled to 0 °C and then LiAlH4 (311 mg, 8.18 mmol) was added. The reaction mixture
was stirred for 5 h at 0 °C and then quenched with water (50 mL). The mixture was stirred until
the organic and aqueous layers separated. The mixture was extracted with chloroform (3 × 100
mL). The combined organic layers were washed with brine, dried over anhydrous MgSO4,
filtered, concentrated in vacuo and purified by flash column chromatography using ethyl
acetate/n-hexane (2:1) to give alcohol 14 (R1 = i-Pr, R2 = CH2OH, X = Y = CH, 466 mg, 62
%) as a thick viscous oil.
A flame dried two neck round bottom flask containing oxalyl chloride (370 μL, 4.34 mmol)
in anhydrous DCM was cooled at −78 °C under a nitrogen atmosphere. Next, anhydrous DMSO
(679 mg, 8.7 mmol) was added drop wise via a syringe. The resulting solution was allowed to
stir at −78 °C for 10 min and then alcohol 14 (R1 = i-Pr, R2 = CH2OH, X = Y = CH, 400 mg,
1.74 mmol) dissolved in anhydrous DCM was added gradually via a syringe. The resulting
reaction mixture was allowed to stir for 1 h at −78 °C and then quenched with triethylamine
(1.95 mL, 13.9 mmol) before being allowed to warm to room temperature. The reaction mixture
was extracted with DCM (3 × 50 mL), washed with brine, dried over anhydrous MgSO4,
filtered, and concentrated in vacuo to give aldehyde 15 (R1 = i-Pr, X = Y = CH), which was
used without further purification.
A solution of 15 (R1 = i-Pr, X = Y = CH, 360 mg, 1.58 mmol) in DCM (10 mL) was cooled
at 0 °C and then Ph3P (1.24 gm, 4.74 mmol) and CBr4 (785 mg, 2.37 mmol) were sequentially
added. The resulting mixture was stirred at room temp for 2 h. The reaction mixture was
concentrated in vacuo and the Ph3PO was precipitated by addition of n-hexane and removed
by filtration. The filtrate was concentrated and the residue purified using a filter column (ethyl
acetate/n-hexane as eluent). The resulting material (360 mg, 1.58 mmol) was dissolved in
anhydrous THF and cooled to −78 °C. Next, n-BuLi (121 mg, 1.90 mmol) was gradually added
and the resulting solution stirred for 2 h at −78 °C. The mixture was quenched with water (50
mL), allowed to stir at room temperature for 30 min, and then extracted with ethyl acetate (3
× 100 mL). The combined organic extracts were dried over anhydrous MgSO4, filtered,
concentrated in vacuo and purified by flash column chromatography eluting with ethyl acetate/
n-hexane (5:95) to furnish 1-(1-methylethyl)-2-propyn-1-yl]oxy]naphthalene(16, R1 = i-Pr, X
= Y = CH, 282 mg, 72 %) as a white solid.
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General procedure for the preparation of 1-H-1,2,3-triazoles 17. Exemplified for 1-(4-
chlorophenyl)-4-(2-methyl-1-(1-naphthalenyloxy)propyl)-1H-1,2,3-triazole (24)
A single neck round bottom flask under an argon atmosphere was charged with 16 (R1 = i-Pr,
X = Y = CH, 114 mg, 0.51 mmol), anhydrous acetonitrile (5 mL), 1-azido-4-chlorobenzene
(78.3 mg, 0.51 mmol) and DIPEA (254 μL, 1.53 mmol). The reaction mixture was allowed to
stir at room temperature for 10 min and then finely powdered CuI (194.2 mg, 1.02 mmol) was
added portion wise. After 30 min of stirring at room temperature, the reaction mixture was
quenched with saturated aqueous NH4Cl, diluted with water (50 mL) and extracted with
chloroform (3 × 50 mL). The combined organic extracts were washed with brine, dried over
anhydrous MgSO4, filtered, concentrated in vacuo and purified by flash column
chromatography using ethyl acetate/n-hexane (a gradient of 10–20%) to furnish 24 (167 mg,
87 %) as a gelatinous solid. 1H NMR (CDCl3, 400 MHz) δ 1.16, 1.20 (dd, J = 6.5, 22.0 Hz,
6H), 2.47–2.53 (m, 1H), 5.55 (d, J = 5.0 Hz, 1H), 6.80 (d, J = 8.0 Hz, 1H), 7.25 (m, 1H), 7.37–
7.43(m, 3H), 7.49 (m, 2H), 7.61 (d, J = 9.0 Hz, 2H), 7.79 (m, 2H), 8.38 (m, 1H); ESI-HRMS
for C22H21ClN3O (M+H)+ calcd. 378.1373; found 378.1383.
1-(4-chlorophenyl)-4-(1-(naphthalene-1-yloxy)ethyl)-1H-1,2,3-triazole (23): mp 98–100 °
C; 1H NMR (CDCl3, 400 MHz) δ 1.91 (d, J = 6.0 Hz, 3H) 5.90 (q, J = 6.8, 12.8 Hz, 1H), 6.92
(d, J = 7.2 Hz, 1H), 7.26 (s, 1H), 7.31 (t, J =8.8 Hz, 1H), 7.41–7.51 (m, 5H), 7.63 (d, J = 8.0
Hz, 2H), 7.80 (m, 1H), 7.88 (s, 1H), 8.34 (m, 1H); 13C NMR (CDCl3, 100 MHz) δ 22.56, 69.90,
107.02, 119.08, 120.98, 121.87, 122.19, 125.53, 126.07, 126.14, 126.66, 127.80, 130.07,
134.73, 134.82, 135.64, 151.38, 153.21; ESI-HRMS for C20H17ClN3O (M+H)+ calcd.
350.1060; found 350.1074.
1-(2,6-dichlorophenyl)-4-(1-(naphthalen-1-yloxy)ethyl)-1H-1,2,3-triazole (25): yield 86
%; Gelatinous solid; 1H NMR (CDCl3, 500 MHz) δ 1.98 (d, J = 6.0 Hz, 3H), 5.92 (q, J = 6.5,
13.0 Hz, 1H), 6.91 (d, J = 8.0 Hz, 1H), 7.26 (s, 1H), 7.31 (t, J = 8.0 Hz, 1H), 7.37–7.49 (m,
6H), 7.79 (m, 1H) 8.32 (m, 1H); ESI-HRMS for C20H16Cl2N3O (M+H)+ calcd. 384.0670;
found 384.0672.
4-(1-(4-chloronaphthalen-1-yloxy)ethyl)-1-(4-chlorophenyl)-1H-1,2,3-triazole (26): yield
84 %; Gelatinous solid; 1H NMR (CDCl3, 500 MHz) δ 1.91 (d, J = 6.5 Hz, 3H), 5.86 (q, J =
6.5, 13.5 Hz, 1H), 6.85 (d, J = 8.0 Hz, 1H), 7.26 (s, 1H), 7.39 (d, J = 8.5 Hz, 1H), 7.46 (d, J =
8.5 Hz, 1H), 7.56 (t, J = 8.5 Hz, 1H), 7.62 (t, J = 8.0 Hz, 3H), 7.87 (s, 1H), 8.20 (d, J = 8.5 Hz,
1H), 8.36 (d, J = 8.5 Hz, 1H); ESI-HRMS for C20H16Cl2N3O (M+H)+ calcd. 384.0670; found
384.0684.
4-(1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethoxy)quinoline (27): yield 91 %; mp 128–
130 °C; 1H NMR (CDCl3, 400 MHz) δ 1.95 (d, J = 6.4 Hz, 3H), 5.97 (q, J = 6.4, 12.8 Hz, 1H),
6.89 (d, J = 5.2 Hz, 1H), 7.47 (d, J = 8.8 Hz, 2H), 7.53 (t, J = 8.0 Hz, 1H), 7.64 (d, J = 8.8 Hz,
2H), 7.71 (t, J = 7.2 Hz, 1H), 7.91 (s, 1H), 8.03 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 7.6 Hz, 1H),
8.70 (d, J = 4.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 22.21, 70.05, 102.42, 119.17, 121.92,
121.99, 125.93, 129.23, 130.06, 130.14, 134.98, 135.48, 149.59, 150.01, 151.51, 160.17; ESI-
HRMS for C19H16ClN4O (M+H)+ calcd. 351.1013, found 351.1002. Purity as determined by
HPLC analysis was 94.7%.
4-((1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)methoxy)quinoline (28): yield 89 %; mp 230–
232 °C; 1H NMR (CDCl3, 400 MHz) δ 5.50 (s, 2H), 6.34 (d, J = 8.0 Hz, 1H), 7.39 (t, J = 7.2
Hz, 1H), 7.47 (d, J = 8.4 Hz, 2H), 7.57–7.65 (m, 4H), 7.74 (d, J = 8.0 Hz, 1H), 7.77 (s, 1H),
8.46 (d, J = 8.0 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 48.81, 111.20, 115.77, 120.21, 121.92,
124.28, 127.49, 127.58, 130.24, 132.75, 135.29, 139.87, 143.11, 143.93, 178.46; ESI-HRMS
for C18H14ClN4O (M+H)+ calcd. 337.0856, found 337.0847.
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4-(1-(1-(3,4-dichlorophenyl)-1H-1,2,3-triazol-4-yl)ethoxy)quinoline (29): yield 89 %; mp
62–64 °C; 1H NMR (CDCl3, 400 MHz) δ 1.95 (d, J = 6.4 Hz, 3H), 5.97 (q, J = 6.4, 12.8 Hz,
1H), 6.87 (d, J = 5.6 Hz, 1H), 7.26 (s, 1H), 7.53 (t, J = 7.6 Hz, 1H), 7.57 (s, 2H), 7.71 (t, J =
7.2 Hz, 1H), 7.85 (s, 1H), 7.91 (s, 1H), 8.03 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 8.70
(d, J = 4.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 22.21, 69.96, 102.37, 119.13, 119.69,
121.72, 121.97, 122.50, 125.98, 129.26, 130.10, 131.68, 133.35, 134.23, 135.98, 149.61,
150.28, 151.50, 160.10; Anal. (C19H14Cl2N4O) C, H, N.
4-(4-(1-(quinolin-4-yloxy)ethyl)-1H-1,2,3-triazol-1-yl)benzonitrile (30): yield 87 %; mp
176–178 °C; 1H NMR (CDCl3, 400 MHz) δ 1.96 (d, J = 6.8 Hz, 3H), 5.98 (q, J = 6.0, 12.8 Hz,
1H), 6.87 (d, J = 4.8 Hz, 1H), 7.26 (s, 1H), 7.54 (t, J = 7.2 Hz, 1H), 7.72 (t, J = 7.2 Hz, 1H),
7.80 (d, J = 8.8 Hz, 2H), 7.88 (d, J = 8.0 Hz, 2H), 8.03 (m, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.70
(s, 1H); 13C NMR (CDCl3, 100 MHz) δ 22.16, 69.90, 102.35, 112.86, 117.78, 118.98, 120.82,
121.94, 126.02, 129.25, 130.15, 134.11, 139.74, 149.59, 150.55, 151.45, 160.07; ESI-HRMS
for C20H16N5O (M+H)+ calcd. 342.1355, found 342.1355.
2-chloro-4-(4-(1-(quinolin-4-yloxy)ethyl)-1H-1,2,3-triazol-1-yl)benzonitrile (31): yield 85
%; mp 194–196 °C; 1H NMR (CDCl3, 400 MHz) δ 1.96 (d, J = 6.8 Hz, 3H), 5.98 (q, J = 6.0,
12.8 Hz, 1H), 6.84 (d, J = 4.8 Hz, 1H), 7.54 (t, J = 7.2 Hz, 1H), 7.72 (t, J = 8.0 Hz, 1H), 7.79
(q, J = 8.4, 15.2 Hz, 2H), 7.97 (s, 1H), 8.00 (s, 1H), 8.04 (d, J = 8.8 Hz, 1H), 8.23 (d, J = 8.0
Hz, 1H), 8.69 (d, J = 4.8 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 22.14, 69.81, 102.29, 113.53,
115.12, 118.60, 119.02, 121.51, 121.65, 121.91, 126.06, 129.27, 130.18, 135.53, 138.93,
140.24, 149.60, 150.82, 151.43, 159.98; ESI-HRMS for C20H15ClN5O (M+H)+ calcd.
376.0965, found 376.0975.
(R)-4-(1-(1-(3,4-dichlorophenyl)-1H-1,2,3-triazol-4-yl)ethoxy)quinoline (32): yield 91 %;
mp 62–64 °C; 1H NMR (CDCl3, 400 MHz) δ 1.95 (d, J = 6.8 Hz, 3H), 5.97 (q, J = 6.4, 12.8
Hz, 1H), 6.87 (d, J = 5.2 Hz, 1H), 7.54 (t, J = 7.2 Hz, 1H), 7.58 (s, 2H), 7.72 (t, J = 7.2 Hz,
1H), 7.85 (s, 1H), 7.91 (s, 1H), 8.05 (d, J = 8.8 Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 8.70 (bs,
1H); ESI-HRMS for C19H15N4OCl2 (M+H)+ calcd. 385.0623; found 385.0605.
(S)-4-(1-(1-(3,4-dichlorophenyl)-1H-1,2,3-triazol-4-yl)ethoxy)quinoline (33): yield 89 %;
mp 64–66 °C; 1H NMR (CDCl3, 400 MHz) δ 1.95 (d, J = 6.8 Hz, 3H), 5.98 (q, J = 6.8, 12.8
Hz, 1H), 6.88 (d, J = 4.8 Hz, 1H), 7.54 (t, J = 6.4 Hz, 1H), 7.58 (d, J = 1.2 Hz, 2H), 7.72 (m,
1H), 7.85 (m, 1H), 7.91 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 8.70 (d, J
= 5.6 Hz, 1H); ESI-HRMS for C19H15N4OCl2 (M+H)+ calcd. 385.0623; found 385.0628.
(R)-2-chloro-4-(4-(1-(quinolin-4-yloxy)ethyl)-1H-1,2,3-triazol-1-yl)benzonitrile (34):
yield 92 %; mp 176–178 °C; 1H NMR (CDCl3, 400 MHz) δ 1.96 (d, J = 6.0 Hz, 3H), 5.98 (q,
J = 6.0, 12.8 Hz, 1H), 6.84 (d, J = 5.6 Hz, 1H) 7.55 (t, J = 7.2 Hz, 1H), 7.71–7.83 (m, 3H),
7.97 (m, 2H), 8.04 (d, J = 8.4 Hz, 1H), 8.28 (d, J = 8.8 Hz, 1H), 8.70 (d, J = 5.2 Hz, 1H); ESI-
HRMS for C20H15N5OCl (M+H)+ calcd. 376.0965; found 376.0964.
(S)-2-chloro-4-(4-(1-(quinolin-4-yloxy)ethyl)-1H-1,2,3-triazol-1-yl)benzonitrile (35):
yield 91 %; mp 176–178 °C; 1H NMR (CDCl3, 400 MHz) δ 1.96 (d, J = 6.8 Hz, 3H), 5.98 (q,
J = 6.0, 12.8 Hz, 1H), 6.84 (d, J = 5.6 Hz, 1H), 7.54 (t, J = 8.0 Hz, 1H), 7.71–7.82 (m, 3H),
7.98 (m, 2H), 8.04 (d, J = 8.0 Hz, 1H), 8.28 (d, J = 8.4 Hz, 1H), 8.70 (d, J = 4.8 Hz, 1H); ESI-
HRMS for C20H15N5OCl (M+H)+ calcd. 376.0965; found 376.0974.
(R)-5-(1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethoxy)quinoline (36): yield 82 %; mp
94–96 °C; 1H NMR (CDCl3, 400 MHz) δ 1.92 (d, J = 6.4 Hz, 3H), 5.89 (q, J = 6.0, 12.8 Hz,
1H), 7.00 (d, J = 8.0 Hz, 1H), 7.40 (dd, J = 3.6, 8.0 Hz, 1H), 7.46 (d, J = 8.4 Hz, 2H), 7.55 (t,
J = 8.4 Hz, 1H), 7.65 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.8 Hz, 1H), 7.88 (s, 1H), 8.65 (d, J =
8.0 Hz, 1H), 8.91 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ 22.36, 70.17, 107.39, 119.10, 120.52,
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121.40, 121.87, 122.32, 129.56, 130.10, 131.00, 134.85, 135.56, 149.36, 150.76, 150.95,
152.95; ESI-HRMS for C19H16N4OCl (M+H)+ calcd. 351.1013; found 351.1002.
4-(1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethoxy)quinoline 1-oxide (37): yield 88 %;
mp 158–160 °C; 1H NMR (d6-DMSO, 400 MHz) δ 1.85 (d, J = 6.8 Hz, 3H), 6.09 (q, J = 6.0,
12.8 Hz, 1H), 7.20 (d, J = 6.8 Hz, 1H), 7.67 (d, J = 8.4 Hz, 2H), 7.74 (t, J = 7.6 Hz, 1H), 7.86
(t, J = 8.4 Hz, 1H), 7.95 (d, J = 9.2 Hz, 2H), 8.25 (d, J = 8.8 Hz, 1H), 8.50 (dd, J = 6.4, 12.0
Hz, 2H), 9.06 (s, 1H); 13C NMR (d6-DMSO, 100 MHz) δ 20.58, 69.53, 103.30, 119.27, 121.56,
121.82, 122.67, 122.80, 128.14, 129.87, 130.79, 133.06, 135.32, 135.48, 140.72, 148.38,
150.38; ESI-HRMS for C19H16N4O2Cl (M+H)+ calcd. 367.0962; found 367.0948.
4-(1-(1-(3,4-dichlorophenyl)-1H-1,2,3-triazol-4-yl)ethoxy)quinoline 1-oxide (38): yield 92
%; mp 216–218 °C; 1H NMR (d6-DMSO, 400 MHz) δ 1.85 (d, J = 6.0 Hz, 3H), 6.09 (q, J =
6.0, 12.8 Hz, 1H), 7.19 (d, J = 6.4 Hz, 1H), 7.74 (t, J = 8.0 Hz, 1H), 7.86 (m, 2H), 7.98 (d, J
= 9.2 Hz, 1H), 8.26 (m, 2H), 8.50 (dd, J = 7.2, 12.0 Hz, 2H), 9.12 (s, 1H); 13C NMR (d6-DMSO,
100 MHz) δ 20.58, 69.47, 103.33, 119.28, 120.16, 121.74, 121.85, 122.67, 122.78, 128.15,
130.76, 131.09, 131.81, 132.33, 135.39, 136.03, 140.71, 148.53, 150.21; ESI-HRMS for
C19H15N4O2Cl2 (M+H)+ calcd. 401.0571 found 401.0566.
5-(1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethoxy)quinoline 1-oxide (39): yield 81 %;
mp 165–167 °C; 1H NMR (CDCl3, 400 MHz) δ 1.93 (d, J = 6.0 Hz, 3H), 5.90 (q, J = 6.8 12.8
Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H) 7.26 (t, J = 6.0 Hz, 1H), 7.47 (d, J = 8.4 Hz, 2H), 7.60 (t, J
= 8.4 Hz, 1H), 7.65 (d, J = 8.4 Hz, 2H), 7.91 (s, 1H), 8.20 (d, J = 8.4 Hz, 1H) 8.29 (d, J = 9.2
Hz, 1H), 8.53 (d, J = 5.2 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 22.27, 70.58, 109.66, 112.34,
119.20, 120.13, 121.03, 121.91, 123.94, 130.26, 130.73, 135.01, 135.49, 136.33, 142.76,
150.15, 153.56; ESI-HRMS for C19H16N4O2Cl (M+H)+ calcd. 367.0962; found 367.0977.
Purity as determined by HPLC analysis was 94.3%.
(R)-4-(1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethoxy)quinoline 1-oxide (40): yield 91
%; mp 172–174 °C; 1H NMR (CDCl3, 400 MHz) δ 1.96 (d, J = 8.8 Hz, 3H), 5.92 (q, J = 6.0,
12.8 Hz, 1H), 6.88 (d, J = 6.8 Hz, 1H), 7.48 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 8.8 Hz, 3H), 7.80
(t, J = 7.2 Hz, 1H), 7.96 (s, 1H), 8.28 (d, J = 8.0 Hz, 1H), 8.39 (d, J = 6.8 Hz, 1H), 8.73 (d, J
= 8.4 Hz, 1H); ESI-HRMS for C19H16N4O2Cl (M+H)+ calcd. 367.0962; found 367.0948.
(R)-5-(1-(1-(4-chlorophenyl)-1H-1,2,3-triazol-4-yl)ethoxy)quinoline 1-oxide (41): yield 88
%; mp 184–186 °C; 1H NMR (CDCl3, 400 MHz) δ 1.93 (d, J = 6.0 Hz, 3H), 5.90 (q, J = 6.4,
12.8 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 7.28 (m, 3H), 7.48 (d, J = 9.2 Hz, 2H), 7.61 (t, J = 8.4
Hz, 1H), 7.65 (d, J = 9.2 Hz, 2H), 7.91 (s, 1H), 8.21 (d, J = 8.4 Hz, 1H), 8.30 (d, J = 9.2 Hz,
1H), 8.53 (d, J = 5.2 Hz, 1H); ESI-HRMS for C19H16N4O2Cl (M+H)+ calcd. 367.0962 found
367.0947.
General procedure for the preparation propargyl ether quinoline N-Oxides. Exemplified for
(R)-5-(but-3-yn-2-yloxy)quinoline 1-oxide (16, R1 = (R)-Me, X = N+-O−, Y = CH)
To a 0 °C solution of 16 (R1 = (R)-Me, X = N, Y = CH, 120 mg, 0.61 mmol) in anhydrous
DCM under a nitrogen atmosphere was added m-chloroperbenzoic acid (163 mg, 0.73 mmol,
77 %). The reaction mixture was stirred at room temperature for 2 h, concentrated in vacuo
and purified by flash column chromatography eluting with methanol/chloroform (a gradient
of 5–10 %) to furnish (R)-5-(but-3-yn-2-yloxy)quinoline 1-oxide (16, R1 = (R)-Me, X = N+-
O−, Y = CH, 120 mg, 93 %) as a white solid. mp 156–158 °C; 1H NMR (CDCl3, 400 MHz) δ
1.82 (d, J = 6.8 Hz, 3H), 2.54 (s, 1H), 5.05 (q, J = 6.8, 13.6 Hz, 1H), 7.20 (d, 1H, J = 8.0 Hz,
1H) 7.26 (t, J = 8.0 Hz, 3H), 7.68 (t, J = 9.2 Hz, 1H), 8.15 (d, J = 9.2 Hz, 1H), 8.35 (d, J = 8.8
Hz, 1H), 8.54 (d, J = 5.2 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 22.32, 64.68, 75.09, 81.96,
Maurya et al. Page 10
J Med Chem. Author manuscript; available in PMC 2010 August 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
109.52, 112.49, 120.09, 121.28, 123.85, 130.57, 136.32, 142.64, 153.36; ESI-HRMS for
C13H12NO2 (M+H)+ calcd. 214.0868; found 214.0875.
Evaluation of CPIMPDH inhibition
Determination of IC50 values—Inhibition of recombinant CpIMPDH, purified from E.
coli,12 was assessed by monitoring the production of NADH by fluorescence at varying
inhibitor concentrations (25 pM - 5 μM). IMPDH was incubated with inhibitor for 5 min at
room temperature prior to addition of substrates. The following conditions were used: 50 mM
Tris-HCl, pH 8.0, 100 mM KCl, 3 mM EDTA, 1 mM dithiothreitol (assay buffer) at 25 °C, 10
nM CpIMPDH, 300 μM NAD and 150 μM IMP. To characterize the non-specific binding of
inhibitors, assays were also carried out in the presence of 0.05% BSA (fatty acid free). IC50
values were calculated for each inhibitor according to Equation 1 using the SigmaPlot program
(SPSS, Inc.):
(Eq. 1)
where υi is initial velocity in the presence of inhibitor (I) and υo is the initial velocity in the
absence of inhibitor. Inhibition at each inhibitor concentration was measured in quadruplicate
and averaged; this value was used as υi. The IC50 values were determined three times; the
average and standard deviations are reported.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
This work was supported by funding from the National Institute of Allergy and Infectious Diseases (U01AI075466).
GDC thanks the New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases
(NERCE/BEID), the Harvard NeuroDiscovery Center and the Partners Center for Drug Discovery for financial
support. The authors would also like to thank Prof. Barry Snider (Department of Chemistry, Brandeis University) for
helpful suggestions and Prof. Li Deng (Department of Chemistry, Brandeis University) for use of instrumentation.
Abbreviations
Cp Cryptosporidium parvum
BSA bovine serum albumin
DCM dichloromethane
DIBAL diisobutylaluminum hydride
EDCI 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide
GMP guanosine monophosphate
HTS high throughput screening
IMP inosine 5′-monophosphate
IMPDH inosine 5′-monophosphate dehydrogenase
m-CPBA m-chloroperoxybenzoic acid
NAD+ nicotinamide-adenine dinucleotide
XMP xanthosine 5′-monophosphate
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Figure 1.
CpIMPDH inhibitor identified by HTS.
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Scheme 1.
IMPDH catalyzed conversion of 1 to 3, which is further processed to 4.
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Scheme 2.
General Procedure for the Synthesis of Amide Derivatives.*
*Reagents and conditions: (a) (i) c-PrMgBr, THF, −20 °C, 2 h, (ii) Ph3P, CBr4, DCM, 0 °C, 2
h; (b) 1-naphthol, K2CO3, DMF, rt, 2 h; (c) 3 M NaOH, THF:H2O (2:1), 80 °C, 6 h; (d) 4-
chloroaniline, 0 °C, EDCI·HCl, DCM, rt, 12 h; (e) 4-chloroaniline, cat. DMAP, DCM, rt, 2 h;
(f) 4-hydroxyquinoline, K2CO3, DMF, 0 °C, rt, 12 h.
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Scheme 3.
General Procedure for the Synthesis of 1,2,3-Triazole Derivatives.*
*Reagents and conditions: X and Y = N, CH or CCl. (a) [R1 = Me] MeCH(OH)C=CH, 0 °C,
Ph3P, 10 min, DEAD, rt, 12 h; (b) [R1 = H] BrCH2C=CH, K2CO3, DMF, rt, 12 h; (c) [R1 = i-
Pr, R2 = CO2H] (i) LiAlH4, THF, 0 °C, 4 h, (ii) (COCl)2, DMSO, DCM, Et3N, −78 °C, 3 h;
(d) [R1 = Et, R2 = CO2Et] DIBAL, THF, −78 °C, 6 h; (e) (i) CBr4, Ph3P, DCM, 0 °C, 2 h, (ii)
n-BuLi, THF, −78 °C, 2 h; (f) R3PhN3, CH3CN, DIPEA, CuI, rt, 30 min; (g) m-CPBA, DCM,
0 °C, 12 h.
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Table 1
IC50 determinations for inhibition of CpIMPDH by amide derivatives.
Compound R X
IC50 (μM)a,b
(−) BSAc (+) BSA
18 Me CH 1.06 ± 0.1 1.64 ± 0.2
19 Ph CH > 5 NDd
20 i-Pr CH 0.71 ± 0.1 0.83 ± 0.2
21 c-Pr CH > 5 ND
22 Me N 0.66 ± 0.2 0.86 ± 0.2
a
Positive control: 5; IC50 = 3.3 ± 0.2 μM.
b
IC50 ± SD were determined from three independent experiments.
c
0.05% Fatty acid free bovine serum albumin.
d
Not Determined.
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